Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EVO
stocks logo

EVO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast EVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVO is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast EVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVO is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
1 Sell
Moderate Buy
Current: 3.230
sliders
Low
5.00
Averages
6.00
High
7.00
Current: 3.230
sliders
Low
5.00
Averages
6.00
High
7.00
RBC Capital
Outperform -> NULL
downgrade
2025-11-12
Reason
RBC Capital
Price Target
2025-11-12
downgrade
Outperform -> NULL
Reason
RBC Capital lowered the firm's price target on Evotec to EUR 10 from EUR 11.20 and keeps an Outperform rating on the shares.
RBC Capital
Charles Weston
Outperform
downgrade
2025-09-03
Reason
RBC Capital
Charles Weston
Price Target
2025-09-03
downgrade
Outperform
Reason
RBC Capital analyst Charles Weston lowered the firm's price target on Evotec to EUR 11.20 from EUR 11.90 and keeps an Outperform rating on the shares.
H.C. Wainwright
Douglas Tsao
Buy
downgrade
$8 -> $7
2025-08-14
Reason
H.C. Wainwright
Douglas Tsao
Price Target
$8 -> $7
2025-08-14
downgrade
Buy
Reason
H.C. Wainwright analyst Douglas Tsao lowered the firm's price target on Evotec to $7 from $8 and keeps a Buy rating on the shares following the Q2 report. The firm says softness in biotech funding could continue to hurt the company's revenue in the near-term.
Deutsche Bank
Fynn Scherzler
Hold
downgrade
2025-07-22
Reason
Deutsche Bank
Fynn Scherzler
Price Target
2025-07-22
downgrade
Hold
Reason
Deutsche Bank analyst Fynn Scherzler lowered the firm's price target on Evotec to EUR 6 from EUR 7 and keeps a Hold rating on the shares.
RBC Capital
Charles Weston
Outperform
maintain
2025-05-15
Reason
RBC Capital
Charles Weston
Price Target
2025-05-15
maintain
Outperform
Reason
RBC Capital analyst Charles Weston raised the firm's price target on Evotec to EUR 11.90 from EUR 11.60 and keeps an Outperform rating on the shares.
Deutsche Bank
Sell -> Hold
upgrade
2025-04-24
Reason
Deutsche Bank
Price Target
2025-04-24
upgrade
Sell -> Hold
Reason
Deutsche Bank upgraded Evotec to Hold from Sell with a price target of EUR 7, up from EUR 4. The company provided new guidance for 2025 and the medium term, "offering much-needed direction," the analyst tells investors in a research note. The firm says the guidance appears achievable. Although the projected adjusted EBITDA level is "disappointing and should lead to significant consensus earnings cuts, it should provide a reasonable floor" for the shares, contends Deutsche Bank.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Evotec SE (EVO.O) is -6.37, compared to its 5-year average forward P/E of 458.84. For a more detailed relative valuation and DCF analysis to assess Evotec SE 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
458.84
Current PE
-6.37
Overvalued PE
2552.93
Undervalued PE
-1635.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
36.30
Current EV/EBITDA
16.75
Overvalued EV/EBITDA
57.54
Undervalued EV/EBITDA
15.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
4.79
Current PS
1.23
Overvalued PS
8.09
Undervalued PS
1.49
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

EVO News & Events

Events Timeline

(ET)
2025-12-01
07:50:00
Leerink Initiates Coverage of Evommune with Outperform Rating and $42 Price Target
select
2025-12-01
07:22:00
Evercore ISI Initiates Coverage of Evommune with Outperform Rating and $40 Price Target
select
2025-12-01
07:21:00
Cantor Fitzgerald Initiates Overweight Rating on Evommune, Highlights EVO756 Potential
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-12SeekingAlpha
Evotec Receives $5M Milestone Payment from Bristol Myers Following FDA Approval of New Drug Application

  • Milestone Payment: Evotec SE has received a $5 million milestone payment from Bristol Myers Squibb following the FDA's acceptance of an investigational new drug application related to their partnership.

  • Drug Development: The drug candidate, a cereblon E3 ligase modulator, is set to enter Phase 1 clinical trials in 2026 as part of the collaboration between Evotec and Bristol Myers Squibb.

[object Object]
Preview
9.5
11-05SeekingAlpha
Evotec SE announces third quarter results

  • Q3 Financial Performance: Evotec SE reported a 7.1% decrease in group revenues to €535.1 million for Q3, with a 12.3% decline in D&PD revenues attributed to soft demand in early drug discovery services.

  • Adjusted EBITDA and Costs: The adjusted Group EBITDA was €(16.9) million, impacted by underutilization and high fixed costs in the D&PD segment, along with expenses related to the JEB Toulouse facility ramp-up.

  • Future Outlook: The company targets a compound annual growth rate (CAGR) of 8-12% for group revenues from 2024 to 2028, with an expected adjusted EBITDA margin above 20% by 2028.

  • 2025 Guidance: Evotec confirmed its guidance for 2025, projecting group revenues between €760-800 million and adjusted Group EBITDA of €30-50 million, alongside R&D expenditures of €40-50 million.

[object Object]
Preview
8.5
11-05NASDAQ.COM
Sandoz to Purchase Just-Evotec Biologics EU SAS in Strategic Move to Expand Biosimilars Portfolio

  • Strategic Acquisition: Sandoz has signed a definitive agreement to acquire Just-Evotec Biologics EU SAS (JEB SAS) for approximately US$350 million, enhancing its capabilities in the biosimilar market.

  • Long-term Goals: The acquisition aligns with Sandoz's strategy to enter the projected US$300 billion biosimilar market and includes a technology license for continuous manufacturing, covering an unlimited number of molecules.

  • Financial Structure: The deal restructures the partnership model with incentives based on license fees and development milestones, potentially totaling around USD 300 million in the coming years.

  • Closing Conditions: The transaction is expected to close in 2025, pending regulatory approvals, and will result in JEB SAS employees joining Sandoz.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Evotec SE (EVO) stock price today?

The current price of EVO is 3.23 USD — it has increased 1.25 % in the last trading day.

arrow icon

What is Evotec SE (EVO)'s business?

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

arrow icon

What is the price predicton of EVO Stock?

Wall Street analysts forecast EVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVO is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Evotec SE (EVO)'s revenue for the last quarter?

Evotec SE revenue for the last quarter amounts to 194.02M USD, decreased -1.01 % YoY.

arrow icon

What is Evotec SE (EVO)'s earnings per share (EPS) for the last quarter?

Evotec SE. EPS for the last quarter amounts to -0.28 USD, decreased -51.72 % YoY.

arrow icon

What changes have occurred in the market's expectations for Evotec SE (EVO)'s fundamentals?

The market is revising Downward the revenue expectations for Evotec SE (EVO) for FY2025, with the revenue forecasts being adjusted by -0.34% over the past three months. During the same period, the stock price has changed by -7.18%.
arrow icon

How many employees does Evotec SE (EVO). have?

Evotec SE (EVO) has 4827 emplpoyees as of December 05 2025.

arrow icon

What is Evotec SE (EVO) market cap?

Today EVO has the market capitalization of 1.15B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free